BAV patients are often excluded from TAVR trials, creating uncertainty about the best way to treat that population when aortic valve replacement is required. To learn more, researchers tracked CMS data from 2018 to 2022, presenting their findings in The Annals of Thoracic Surgery.

SCAI President James Hermiller, MD, recently outlined the key achievements for 2024, including creation of the first interventional cardiology match program, successful advocacy and efforts to increase women in the field.

New expert recommendations from the American College of Cardiology were designed to help cardiologists, primary care physicians, emergency physicians, rheumatologists and other clinicians deliver the best care possible when managing suspected myocarditis. 

FDA Commissioner Robert Califf, MD, talked to Cardiovascular Business about healthcare spending, inconsistent patient outcomes and much more.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Back in 2019, the FDA issued a warning about the use of paclitaxel-coated devices when treating peripheral artery disease. The agency took back that warning in 2023, but it appears to have made a significant impact on patient care. 

The care team behind the very first robotic aortic valve replacement and coronary artery bypass surgery has written about the experience in The Annals of Thoracic Surgery. The group discussed the development of the technique, how the patient was chosen for treatment and other key details.

The heightened risks were even seen in women who were never diagnosed with a psychiatric disorder. It remains unclear why the same trend was not seen in men.